Straits Times Index
3,309.92 +9.92 (+0.30%) Nikkei
38,597.64 -35.38 (-0.09%) Hang Seng
18,066.76 -268.56 (-1.46%) FTSE 100
8,272.46 +67.35 (+0.82%) Bitcoin USD
64,582.16 -931.80 (-1.42%) CMC Crypto 200
1,352.96 -7.36 (-0.54%)
HLS Therapeutics Inc. (HLTRF)
| Previous close | 2.4700 |
| Open | 2.4600 |
| Bid | 2.4300 x 40000 |
| Ask | 2.4600 x 40000 |
| Day's range | 2.4600 - 2.4600 |
| 52-week range | 2.4600 - 4.9400 |
| Volume | |
| Avg. volume | 162 |
| Market cap | 79.847M |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.15 (4.21%) |
| Ex-dividend date | 27 Apr 2023 |
| 1y target est | N/A |
- CNW Group
HLS Therapeutics Reports Annual Meeting Results
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 7, 2024.
- CNW Group
New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that results from a Quebec-based retrospective study examining the positive impact of pharmaceutical support programs ("PSPs") on persistence with clozapine treatment have been published in the Journal of Clinical Pharmacology and Therapeutics.
- CNW Group
HLS Therapeutics Announces Q1 2024 Financial Results
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three-month period ended March 31, 2024. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
